Gypenosides counteract hepatic steatosis and intestinal barrier injury in rats with metabolic associated fatty liver disease by modulating the adenosine monophosphate activated protein kinase and Toll-like receptor 4/nuclear factor kappa B pathways
Sign Up to like & getrecommendations! Published in 2022 at "Pharmaceutical Biology"
DOI: 10.1080/13880209.2022.2126503
Abstract: Abstract Context Non-alcoholic fatty liver disease (NAFLD), the most common chronic liver disease, can develop into metabolic associated fatty liver disease (MAFLD). Gypenosides (GP), the main phytochemical component of Gynostemma pentaphylla (Thunb.) Makino (Cucurbitaceae), have… read more here.
Keywords: fatty liver; disease; hepatic steatosis; mafld ... See more keywords